A double-blind, randomized, placebo-controlled Phase II study of ACP-103 in Schizophrenia Patients With Haloperidol-Induced Akathisia.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 May 2016
At a glance
- Drugs Pimavanserin (Primary) ; Haloperidol
- Indications Drug-induced akathisia; Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- 06 May 2016 New trial record.